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MaOBJECTIVES This study sought to determine the incidence and prognostic significance of persistent iron in patients
post–ST-segment elevation myocardial infarction (STEMI).
BACKGROUND The clinical significance of persistent iron within the infarct core after STEMI complicated by acute
myocardial hemorrhage is poorly understood.
METHODS Patientswho sustained an acute STEMIwere enrolled in a cohort study (BHFMR-MI [Detection and Significance
of Heart Injury in ST Elevation Myocardial Infarction]). Cardiac magnetic resonance imaging including T2* (observed time
constant for the decay of transverse magnetization seen with gradient-echo sequences) mapping was performed at 2 days
and 6months post-STEMI.Myocardial hemorrhage or ironwas defined as a hypointense infarct corewith T2* signal<20ms.
RESULTS A total of 203 patients (age 57  11 years, n ¼ 158 [78%] male) had evaluable T2* maps at 2 days and
6 months post-STEMI; 74 (36%) patients had myocardial hemorrhage at baseline, and 44 (59%) of these patients had
persistent iron at 6 months. Clinical associates of persistent iron included heart rate (p ¼ 0.009), the absence of a history
of hypertension (p ¼ 0.017), and infarct size (p ¼ 0.028). The presence of persistent iron was associated with worsening
left ventricular (LV) end-diastolic volume (regression coefficient: 21.10; 95% confidence interval [CI]: 10.92 to 31.27;
p < 0.001) and worsening LV ejection fraction (regression coefficient: 6.47; 95% CI: 9.22 to 3.72; p < 0.001).
Persistent iron was associated with the subsequent occurrence of all-cause death or heart failure (hazard ratio: 3.91; 95%
CI: 1.37 to 11.14; p ¼ 0.011) and major adverse cardiac events (hazard ratio: 3.24; 95% CI: 1.09 to 9.64; p ¼ 0.035)
(median follow-up duration 1,457 days [range 233 to 1,734 days]).
CONCLUSIONS Persistent iron at 6 months post-STEMI is associated with worse LV and longer-term health out-
comes. (Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction [BHF MR-MI]; NCT02072850)
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1249AB BR E V I A T I O N S
AND ACRONYM S
CMR = cardiac magnetic
resonance
LV = left ventricular
MACE = major adverse cardiac
event(s)
STEMI = ST-segment elevation
ardial infarctionM yocardial hemorrhage (1) and microvas-cular obstruction (2) are common andprognostically important complications
of reperfused ST-segment elevation myocardial
infarction (STEMI), and they are independently
associated with adverse remodeling and heart failure
in the longer term (2). The improvements in survival
after acute STEMI in recent decades translate to
more surviving patients with injured hearts who are
at risk of developing longer-term complications
(3,4). Because there are no evidence-based treat-
ments for microvascular obstruction and myocardial
hemorrhage, more research is needed to understand
the pathophysiology of these disorders more fully.SEE PAGE 1257Myocardial hemorrhage is a result of severe
microvascular injury, with extravasation of erythro-
cytes secondary to loss of endothelial integrity
(1,5–8). Hemoglobin degradation products are toxic
(9–11), and their persistence is evidenced by immu-
nohistochemical staining of iron within macrophages
reflecting sustained inflammation within the infarct
zone (10). Information relating to the clinical signifi-
cance of persistent iron within the infarct core in
patients with acute STEMI complicated by myocardial
hemorrhage has been limited (e.g., sample size of
n # 40 [11–13]), and prognostic data on health out-
comes are lacking.
We aimed to determine the incidence of persistent
iron in a large cohort of STEMI survivors using
contemporary T2* (observed time constant for the
decay of transverse magnetization seen with
gradient-echo sequences) mapping (14,15). Addition-
ally, we aimed to identify which clinical characteris-
tics would be associated with persistent iron and
whether persistent iron may be associated with
adverse clinical outcomes.
We hypothesized that persisting iron would: 1) be
associated with markers of the initial severity of
STEMI; 2) present with distinct clinical characteristics
when compared with resolved iron; 3) be associated
with adverse myocardial remodeling; and 4) be
associated with a worse prognosis in the longer term.
METHODS
The full methodology has been reported previously
(16–19) and is detailed in the Online Methods.
CARDIAC MAGNETIC RESONANCE IMAGE ANALYSIS.
Cardiac magnetic resonance (CMR) imaging analysis
was performed on a Siemens workstation (Siemen
Healthcare, Erlangen, Germany). Left ventricular (LV)
volumes and ejection fraction were assessed usingcomputer-assisted planimetry (syngo.MR,
Siemens Healthcare).
T2* measurement and myocardial hemorrhage. LV
contours were delineated with computer-
assisted planimetry on the raw T2* image
and then copied onto color-coded spatially
co-registered maps (Online Methods). Re-
gions of interest were drawn in the infarct
area surrounding core, core, and remote
zones. Myocardial hemorrhage at 2 days and iron at
6 months were defined as regions of signal
intensity <20 ms within the infarcted area and were
measured as a percentage of LV mass and as a
percentage of infarct size (20–22). Each T2* map was
assessed by 2 independent CMR analysts for the
presence of myocardial hemorrhage or iron.
T2 measurement and myocardial edema. LV contours on
the last corresponding T2 (the transverse relaxation
time)-weighted raw image with an echo time of 55 ms
were planimetered and then copied to the map (23).
Regions of interest were drawn in the surrounding
infarct and remote zones. The extent of myocardial
edema was defined as LV myocardium with
pixel values (T2) >2 SD from remote myocardium
(23,24).
Infarct definition and size. The territory of infarction
was quantified using computer-assisted planimetry
and was expressed as a percentage of LV mass (25).
Myocardial salvage. Myocardial salvage was calculated
by subtraction of percentage of infarct size from
percentage of myocardial edema (7,26,27). The
myocardial salvage index was calculated by dividing
the myocardial salvage area by the initial percentage
of myocardial edema.
Adverse remodeling. Adverse remodeling was defined
as an increase in LV end-diastolic volume at 6 months
from baseline by 20% or more (17).
HEALTH OUTCOMES. We pre-specified adverse
health outcomes that are implicated in the patho-
physiology and natural history of STEMI. The primary
composite outcome was all-cause death or first heart
failure event (hospitalization for heart failure or
defibrillator implantation) following the 6-month
CMR scan. The secondary composite outcome was
major adverse cardiac events (MACE).
STATISTICAL ANALYSIS. The full statistical methods
are reported in the Online Methods. All p values
were 2-sided. A p value >0.050 indicated the
absence of a statistically significant effect. Analyses
were performed using SPSS version 22 for Windows
(SPSS, Inc., Chicago, Illinois), or R version 3.3.0
(R Foundation for Statistical Computing, Vienna,
Austria).
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TABLE 1 Characteristics of 203 Patients With Serial T2* Mapping 2 Days and 6 Months Post-STEMI, Grouped According to the Presence of Hemorrhage
at 2 Days and the Persistence or Absence of Iron Within the Infarct Zone at 6 Months*
All Patients
(N ¼ 203)
No Acute Myocardial
Hemorrhage
(n ¼ 129, 64%)
Acute Myocardial Hemorrhage
6 Months
p Value†
R vs. P
Resolved (R)
(n ¼ 30, 41%)‡
Persisting (P)
(n ¼ 44, 59%)‡
Age, yrs 57  11 58  11 56  12 57  12 0.619
Male 158 (78) 93 (72) 25 (83) 40 (91) 0.471
Hypertension 61 (30) 37 (29) 14 (47) 10 (23) 0.043
Presenting characteristics
Heart rate, beats/min 78  16 77  16 72  14 85  16 0.001
Culprit artery
Left anterior descending 81 (40) 45 (35) 7 (23) 29 (66)
Left circumflex 35 (17) 18 (14) 10 (33) 7 (16) 0.001
Right coronary 87 (43) 66 (51) 13 (43) 8 (18)
Symptom onset to reperfusion, min 175 (122, 327) 170 (122, 310) 177 (129, 381) 208 (114, 402) 0.458
Reperfusion strategy
Primary PCI 191 (94) 124 (96) 27 (90) 40 (91)
Rescue PCI (failed thrombolysis) 8 (4) 2 (2) 2 (7) 4 (9) 0.637
Successful thrombolysis 4 (2) 3 (2) 1 (3) 0 (0)
Blood results on admission
Troponin I, ng/l 2,224 (684, 5,677) 1–28,406 1,567 (528, 2,784) 1–16,609 3,644 (439, 6,516) 3–8,561 6,531 (2,774, 10,330) 55–28,406 0.028
Values are mean  SD, n (%), or median (Q1, Q3). *Age, sex, and variables that differ between the groups are reported. The full table is reported in Online Table 1. †The p values were obtained from Student’s
t test, Fisher exact test or Mann-Whitney U test for comparisons between groups with resolved and persistent iron. ‡Percentage of patients with hemorrhage at 2 days (n ¼ 74).
PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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Of 343 patients with STEMI referred for emergency
percutaneous coronary intervention, 300 underwent
serial CMR, 2.2  1.9 days and 6 months after hospital
admission. A total of 203 patients were included in
the final analysis. The flow diagram for the study is
shown in Online Figure 1. Please also refer to the
Online Results.
PATIENTS’ CHARACTERISTICS. The characteristics
of patients with paired evaluable T2* data (n ¼ 203)
are shown in Table 1 and Online Table 1. The mean  SD
age was 57  11 years, and 78% were male.
A total of 74 (36%) patients had acute myocardial
hemorrhage, and 44 (59%) of these patients had evi-
dence of persistent iron at 6 months. No patients had
de novo myocardial hemorrhage between the 2-day
and 6-month scans.
Compared with patients with resolved hemor-
rhage from baseline, patients with persistent iron
were less likely to have a history of hypertension,
and they had higher heart rates at presentation
(Table 1). The culprit artery was more likely to be
the left anterior descending coronary artery, and
these patients had higher peak troponin levels post-
STEMI (Table 1).
CMR FINDINGS. CMR findings were ascertained dur-
ing the index hospitalization and at 6 months. TheCMR findings are summarized in Table 2 and Online
Table 2.
CMR findings during the index hospitalization. The mean
size of hemorrhage at baseline was 26.9  15.2% of
infarct size. All patients with acute myocardial hem-
orrhage had microvascular obstruction.
At 2-day CMR, patients with persisting iron had
lower LV ejection fractions, larger LV end-systolic
volumes, larger infarctions, a greater burden of
microvascular obstruction, and a larger area of
myocardial edema at baseline, compared with pa-
tients with resolved iron (Table 2). There was no
difference in T2 signal in the infarct zone at baseline
(Table 2).
CMR findings at 6 months. In patients with persistent
iron, the extent of hemorrhage or iron (percentage of
infarct size) reduced in size from baseline to follow-
up (26.2  12.8% vs. 10.6  9.4%; p < 0.001) (Table 2).
At 6 months, in patients with persistent iron, LV
ejection fractionwas lower and LV volumes and infarct
size were higher comparedwith patients with resolved
iron (Table 2). T2* values within the infarct zone were
lower at 6 months in patients with persisting iron
(Table 2, Online Figure 2). Compared with patients
without hemorrhage at baseline, patients with hem-
orrhage at baseline had higher T2 values within the
infarct zone at 6 months (58.7  4.9 ms vs. 55.9  3.7
ms; p < 0.001). Additionally, patients with persisting
iron had higher infarct zone T2 values than patients
TABLE 2 CMR Findings at Baseline and at 6 Months in 203 Patients With STEMI Grouped According to the Presence of Hemorrhage at
2 Days and the Persistence or Absence of Iron Within the Infarct Zone at 6 Months*
All Patients
(N ¼ 203)
No Acute Myocardial
Hemorrhage
(n ¼ 129, 64%)
Acute Myocardial Hemorrhage
6 Months
p Value†
R vs. P
Resolved (R)
(n ¼ 30, 49%)‡
Persistent (P)
(n ¼ 44, 59%)‡
CMR findings 2 days post-MI (n ¼ 211)
LV ejection fraction, % 55  10 57  8 54  9 47  10 0.004
LV end-systolic volume, ml
Men 76  27 68  23 78  18 94  31 0.012
Women 54  14 52  13 55  16 71  9 0.117
Edema and infarct characteristics at 2 days
Myocardial edema, % LV mass 32  12 29  11 32  10 42  11 <0.001
Infarct size, % LV mass 18  14 12  10 22  10 33  12 <0.001
Late microvascular obstruction present 102 (50) 30 (23) 30 (100) 44 (100) —
Late microvascular obstruction, % LV mass 2.5  4.4 0.5  1.6 4.1  2.7 7.3  6.4 0.005
Myocardial hemorrhage, % LV mass 8.5  6.1 — 5.8  4.0 10.3  6.6 0.001
Myocardial hemorrhage, % infarct size 26.9  15.2 — 27.2  18.4 26.2  12.8 0.684
CMR findings 6 months post-MI (n ¼ 211)
LV ejection fraction at 6 months, % 62  10 65  7 60  7 53  11 0.001
LV end-systolic volume at 6 months, ml
Men 68  36 55  21 70  21 98  53 0.005
Women 48  17 43  15 55  11 75  14 0.045
Infarct characteristics at 6 months
Infarct size, % LV mass 13  10 9  8 16  7 24  10 <0.001
Myocardial iron, % LV mass 2.4  2.2 — — 2.4  2.2 —
Myocardial iron, % infarct size 10.6  9.4 — — 10.6  9.4 —
Myocardial T2* values at 6 months
T2* infarct at 6 months, ms 25.7  4.4 27.1  4.0 27.0  4.3 21.6  2.7 <0.001
T2* core at 6 months, ms 16.6  2.1 — — 16.6  2.1 —
Values are mean  SD or n (%). *Extent of myocardial hemorrhage and variables that differ between the groups are reported. The full table is reported in Online Table 2.
†The p values were obtained from Student’s t test or Fisher exact test for comparisons between groups with resolved and persistent iron. ‡Percentage of patients with
hemorrhage at 2 days (n ¼ 74).
CMR ¼ cardiac magnetic resonance; LV ¼ left ventricle; MI ¼ myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction.
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iron collectively (59.5  5.5 ms vs. 56.2  3.8 ms;
p ¼ 0.001). There was no difference in T2 values within
the infarct zone in patients with persisting iron
compared with patients with resolved iron (Figures 1A
and 1B, Online Table 2, Online Figure 2).
CLINICAL ASSOCIATES OF PERSISTENT IRON. The
multivariable associates of infarct core iron status at 6
months are shown in Table 3 and Online Table 3. The
main predictors of persisting iron in patients with
acute hemorrhage were a higher heart rate at pre-
sentation, the absence of a history of hypertension,
and infarct size (Table 3).
PERSISTENT IRON AND LV REMODELING. In multi-
variable linear regression, persistent iron at 6
months was associated with worsening LV end-
diastolic volume and worsening LV ejection fraction
(Online Table 4, Online Figure 3). The multivariable
association between persistent iron and adverse
remodeling (odds ratio: 2.89; 95% confidenceinterval: 0.80 to 10.48; p ¼ 0.106) was not statisti-
cally significant.
PERSISTENT IRON AND HEALTH OUTCOME. Health
outcome data were available in 203 (100%) patients.
The median duration of follow-up was 1,457 days
(post-discharge censor duration range 233 to 1,734
days). All-cause death or heart failure following the 6-
month assessment occurred in 14 (7%) patients,
including 4 noncardiovascular deaths, 4 cardiovas-
cular deaths (n ¼ 2 sudden deaths), 1 undetermined
cause of death, and 5 heart failure episodes (hospi-
talization for heart failure [n ¼ 1] and defibrillator
implantation [n ¼ 4]). Persistent iron was associated
with the occurrence of all-cause death or heart failure
(hazard ratio: 3.91; 95% confidence interval: 1.37 to
11.14; p ¼ 0.011) (Figure 2).
MACE following the 6-month assessment
occurred in 13 (6%) patients, including 3 cardio-
vascular deaths (2 sudden deaths), 5 heart failure
episodes (hospitalization for heart failure [n ¼ 1]
FIGURE 1 Two Patients With a Similar Presentation of Acute STEMI
Contrast CMRA
B
2-day T2* map 6-month T2* map 6-month T2 map
The full details are outlined in the Online Appendix. Contrast-enhanced cardiac magnetic resonance 2 days post-STEMI showed anteroseptal
infarct in both patients (left, yellow arrows). (A) Patient with resolved myocardial hemorrhage: T2* mapping at 2 days showed myocardial
hemorrhage (middle left, black arrow) with resolution at 6 months (middle right). The T2 value in the surrounding infarct region was 53 ms
(right). Left ventricular end-diastolic volume was unchanged from 126 to 127 ml in 6 months. This patient had an uncomplicated clinical
course. (B) Patient with persisting iron: T2* mapping at 2 days showed myocardial hemorrhage (middle left, black arrow) that persisted at 6
months (middle right, black arrow). The T2 value in the surrounding infarct region was 55 ms (right). Left ventricular end-diastolic volume
increased from 191 to 228 ml in 6 months. This patient was rehospitalized with new-onset heart failure. STEMI ¼ ST-segment elevation
myocardial infarction.
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STEMIs, and 1 STEMI.
Persistent iron was associated with the occurrence
of MACE (hazard ratio: 3.24; 95% confidence interval:
1.09 to 9.64; p ¼ 0.035) (Figure 2).
Associations with persistent iron and health
outcome were not independent of the initial size of
the infarct.
DISCUSSION
We present a large investigation of persistent iron
within the infarct core, as revealed by T2* mapping,
after acute myocardial hemorrhage in a cohort of
unselected patients with STEMI.
The main findings are as follows: 1) 36% patients
had myocardial hemorrhage at baseline, and 59% of
these patients had evidence of persistent iron at 6
months; 2) de novo myocardial hemorrhage did not
occur after the 2-day CMR scan; 3) clinical associates of
persistent iron included patients’ characteristics
(male sex, smoking status), hemodynamic features at
presentation (heart rate), neutrophil count, andelectrocardiographic, angiographic and imaging mea-
sures of STEMI severity (ST-segment resolution,
Thrombus In Myocardial Infarction flow, infarct size,
myocardial edema); 4) higher heart rate, absence of
hypertension, and larger initial infarct size differen-
tiated patients who had persisting iron from patients
with resolution of iron; 5) persisting iron was associ-
ated with increasing LV end-diastolic volume and
decreasing LV ejection fraction at 6 months; and 6)
persisting iron was associated with an approximately
4-fold increase in the likelihood of all-cause death or
heart failure and a 3-fold increase in the likelihood of
MACE. Taken together, these findings identify
persistent iron residues as a mechanistic explanation
of LV remodeling and worsening function (Figures 1A
and 1B). Potentially, persistent iron represents a ther-
apeutic target, and further research seems warranted.
Our analysis builds on the results of other studies
(11,12,18), and it helps to clarify some conflicting re-
sults (13). In a time-course study of myocardial edema
and hemorrhage by Zia et al. (13), the mean T2*
relaxation time returned to normal by 6 months
post-STEMI, a finding implying that persistent iron is
TABLE 3 Multivariable Associations With 6-Month Iron Status (Resolved or Persisting)
(n ¼ 74) at 6 Months Post-STEMI in Logistic Regression Analysis*
Multivariable Associations Odds Ratio (95% CI)† p Value
Patients’ characteristics and
angiographic data
Heart rate, beats/min 1.08 (1.02–1.14) 0.009
Hypertension 0.12 (0.02–0.68) 0.017
Patients’ characteristics,
angiographic data,
and infarct size‡
Heart rate, beats/min 1.08 (1.01–1.16) 0.020
Hypertension 0.10 (0.01–0.67) 0.018
Infarct size, % LV mass 1.10 (1.01–1.20) 0.028
*Only statistically significant variables are reported. All variables included in the model are described in the
Online Appendix. †The odds ratio (95% CIs) indicates odds of persisting iron at 6 months given exposure to the
independent variable. ‡Similar results were obtained when myocardial edema was included instead of infarct size.
CI ¼ confidence interval; other abbreviations as in Tables 1 and 2.
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persistent iron may be much more common (11,12,18).
We think these differences can be explained by the
emerging availability of T2* mapping methods, which
have improved sensitivity and image quality.
Our results reveal that a history of hypertension
may have a protective effect on the persistence of
iron. In addition, a diagnosis of hypertension was
associated with increasing LV ejection fraction. This
is an unexpected finding, given that previous studies
showed that hypertension is associated with
myocardial hemorrhage acutely (28,29). A history of
hypertension reflects an established diagnosis and
the presence of concomitant antihypertensive drug
therapy initiated before the STEMI event. Further,
persisting iron and acute myocardial hemorrhage
reflect different but related processes. Persisting iron
at 6 months reflects all factors from after reperfusion
to follow-up, whereas myocardial hemorrhage early
post-STEMI is related to acute reperfusion injury. We
also observed no association between the time from
symptom onset to reperfusion and the persistence of
iron. Evidence suggests that ischemic time is associ-
ated with myocardial hemorrhage (6,28,30); however,
studies in the present cohort (18,19) and others (5,11)
have suggested that there is no association. Our re-
sults add to our idea that acute myocardial hemor-
rhage and persisting iron result from distinct
pathological processes.
Bulluck et al. (12) pooled the results from all current
studies of residual iron (11,12,18) and calculated the
prevalence of myocardial hemorrhage as 39 of 73 (53%)
patients, with 28 of 39 (72%) patients having persisting
iron. Adding in our results (which include 30 patients
from the serial imaging substudy by Carrick et al. [18]),
the up-to-date values are 100 of 246 (41%) patients
with myocardial hemorrhage (Kali et al. [11], 11 of 15;
Bulluck et al. [12], 15 of 28; our study, 74 of 203) and 68
of 100 (68%) with persisting iron (Kali et al. [11], 11 of
11; Bulluck et al. [12], 13 of 15; our study, 44 of 74). The
comparatively low incidence of persisting iron in
our study may be a reflection of an unselected,
consecutively recruited, large cohort of patients with
STEMI, with a wide heterogeneity in the severity
of infarcts. For example, in the population studied
by Bulluck et al. (12), the acute infarct size was larger
than in our study (27  15% vs. 18  14%), and the
left anterior descending coronary culprit artery was
predominant (60% vs. 40%). We have found that
both these features are associated with persistence
of iron residues.
Bulluck et al. (12) reported high T2 infarct zone
signal in patients with persisting iron; however, the
number of patients with resolved iron in their cohortwas small (n ¼ 2). Further, none of the patients in the
study by Kali et al. (11) had resolved iron. The
conclusion, therefore, that the persistence of iron
causes edema has not been resolved. In the present
study, myocardial T2 in the infarct zone at 6 months
was higher in patients with acute myocardial hemor-
rhage, but no differences were observed in those pa-
tients with persistent iron compared with those with
resolution (Figures 1A and 1B, Online Table 2). Other
factors may be relevant, including the confounding
problem that STEMI severity is linked with myocardial
hemorrhage. Nonetheless, patients with persisting
iron had higher infarct zone T2 signal than patients
without hemorrhage and those with resolved iron
collectively, a finding that supports a mechanistic ba-
sis for the association between persisting iron and
worsening LV volumes and function. Persistent iron
may represent a nidus to drive local and systemic
inflammation, consistent with our observation of
higher neutrophil counts in patients with persisting
iron. This theory is further supported by a recent
canine study byKali et al. (10), which demonstrated the
presence of proinflammatory cells in areas of iron
deposition post-myocardial infarction.
Our research has important clinical implications.
The persistence of iron defines a high-risk group of
patients post-STEMI. Intramyocardial hemorrhage is
proarrhythmic (31–33), and this feature may
contribute in part to a higher mortality rate in pa-
tients with persisting iron at 6 months. The relation-
ship between persistent iron and worsening health
outcome further highlights the need for therapeutic
interventions to prevent the occurrence of myocar-
dial hemorrhage acutely. We have shown that pa-
tients with a more severe STEMI initially are at higher
risk of persistent iron; therefore, novel treatments
FIGURE 2 Persistent Iron and Adverse Outcomes After STEMI
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Kaplan-Meier survival curve for the relationship between infarct core iron status at 6 months and (A) all-cause death or heart failure and (B)
major adverse cardiac events (censor time 1,457 days [range 233 to 1,734 days]). Persisting iron at 6 months post-ST-segment elevation
myocardial infarction (STEMI) was associated with all-cause death or heart failure and major adverse cardiac events.
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reperfusion. Our results also support the case for
CMR-based risk assessment at 6 months in those pa-
tients with acute myocardial hemorrhage early post-
myocardial infarction to detect persistent infarct
zone iron. Affected patients may benefit from more
intensive therapy. We are uncertain about the justi-
fication for systemic iron chelation therapy as sug-
gested by Bulluck et al. (34), given that iron
deficiency is an adverse prognostic factor in patients
with LV dysfunction (35). The possibility that patients
with acute STEMI could benefit from targeted therapy
to prevent myocardial hemorrhage is currently being
investigated. T-TIME (A Trial of Low-dose Adjunctive
alTeplase During prIMary PCI) (36) is a randomized,
double-blind, placebo-controlled phase II trial of low-
dose intracoronary alteplase in patients with acute
STEMI who present <6 h from symptom onset with
risk factors for microvascular obstruction (e.g., prox-
imal culprit lesion location). T-TIME tests the efficacy
hypothesis that intracoronary thrombolysis will
reduce coronary thrombus burden, restore microvas-
cular perfusion, reduce infarct zone hemorrhage, and
improve surrogate clinical outcomes. The alternate
safety hypothesis that intracoronary lysis will in-
crease infarct zone hemorrhage and persistentmyocardial iron, and thereby have an adverse effect
on surrogate outcomes, will also be assessed.
STUDY LIMITATIONS. Our study lacks pathological
correlation of the imaging results. Further, our results
do not permit mechanistic interpretation regarding
whether inflammation is the primary driver of
persistent iron, or alternatively, persistent iron may
reflect a defect in macrophage-mediated clearance of
hemoglobin degradation products. As a result of time
constraints imposed on the CMR examination, the T2*
imaging protocol involved 3 short-axis slices (base,
mid, apical) rather than a full LV stack, and therefore
minor degrees of hemorrhage could have been
missed. However, imaging positions were prescribed
on anatomic landmarks, and scans were undertaken
in the same laboratory, thus improving our ability to
select the same matched slice positions between
scans. The T2* acquisition was associated with imag-
ing artifacts that limited the quantification of hem-
orrhage and iron in some patients. Future
improvements to T2* mapping could include the use
of high-pass filtered processing (37) and the use of an
automated truncation method (38). Because the sur-
vival analyses included 14 events, we were limited in
the number of confounders we could account for in
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Myocardial
hemorrhage that occurs acutely after STEMI can persist as infarct
core iron in the long term in approximately 3 in 5 patients.
Persistent iron is predictive of worsening LV function and vol-
umes, all-cause death or heart failure, and MACE in the longer
term.
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: The persistence of myocardial iron can be predicted on
the basis of the initial severity of the myocardial infarction. In
patients with acute myocardial hemorrhage, repeat CMR at 6
months may be useful for risk stratification. Patients who present
with more severe infarcts may be targeted with novel treat-
ments, such as intracoronary thrombolysis. Further investigation
is warranted.
TRANSLATIONAL OUTLOOK: Survival analysis was limited
by the small number of events (n ¼ 14). Therefore, the results
are hypothesis generating.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 1 , N O . 9 , 2 0 1 8 Carberry et al.
S E P T E M B E R 2 0 1 8 : 1 2 4 8 – 5 6 Persistent Infarct Core Iron Post-STEMI
1255the statistical models. These results are preliminary,
and further research is warranted.
CONCLUSIONS
Persistent iron within the infarct core is common
(about 3 in 5) in patients with myocardial hemorrhage
early post-STEMI. Persistent iron is predictive of
worsening LV function and volumes, as well as all-
cause death or heart failure and MACE in the longer
term.
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